These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

679 related items for PubMed ID: 8120917

  • 1. Changes in mammographic densities induced by a hormonal contraceptive designed to reduce breast cancer risk.
    Spicer DV, Ursin G, Parisky YR, Pearce JG, Shoupe D, Pike A, Pike MC.
    J Natl Cancer Inst; 1994 Mar 16; 86(6):431-6. PubMed ID: 8120917
    [Abstract] [Full Text] [Related]

  • 2. Pilot trial of a gonadotropin hormone agonist with replacement hormones as a prototype contraceptive to prevent breast cancer.
    Spicer DV, Pike MC, Pike A, Rude R, Shoupe D, Richardson J.
    Contraception; 1993 May 16; 47(5):427-44. PubMed ID: 8390340
    [Abstract] [Full Text] [Related]

  • 3. The prevention of breast cancer through reduced ovarian steroid exposure.
    Spicer DV, Pike MC.
    Acta Oncol; 1992 May 16; 31(2):167-74. PubMed ID: 1622631
    [Abstract] [Full Text] [Related]

  • 4. Reversal of gonadotropin-releasing hormone agonist induced reductions in mammographic densities on stopping treatment.
    Gram IT, Ursin G, Spicer DV, Pike MC.
    Cancer Epidemiol Biomarkers Prev; 2001 Nov 16; 10(11):1117-20. PubMed ID: 11700258
    [Abstract] [Full Text] [Related]

  • 5. Contraception and cancer prevention.
    Ursin G, Spicer DV, Pike MC.
    Adv Contracept Deliv Syst; 1994 Nov 16; 10(3-4):369-86. PubMed ID: 12287845
    [Abstract] [Full Text] [Related]

  • 6. Sex steroids and breast cancer prevention.
    Spicer DV, Pike MC.
    J Natl Cancer Inst Monogr; 1994 Nov 16; (16):139-47. PubMed ID: 7999456
    [Abstract] [Full Text] [Related]

  • 7. Pituitary function is altered during the same cycle in women with polycystic ovary syndrome treated with continuous or cyclic oral contraceptives or a gonadotropin-releasing hormone agonist.
    Ruchhoft EA, Elkind-Hirsch KE, Malinak R.
    Fertil Steril; 1996 Jul 16; 66(1):54-60. PubMed ID: 8752611
    [Abstract] [Full Text] [Related]

  • 8. Exogenous progestins and breast cancer.
    Stanford JL, Thomas DB.
    Epidemiol Rev; 1993 Jul 16; 15(1):98-107. PubMed ID: 8405216
    [Abstract] [Full Text] [Related]

  • 9. The detection of changes in mammographic densities.
    Ursin G, Astrahan MA, Salane M, Parisky YR, Pearce JG, Daniels JR, Pike MC, Spicer DV.
    Cancer Epidemiol Biomarkers Prev; 1998 Jan 16; 7(1):43-7. PubMed ID: 9456242
    [Abstract] [Full Text] [Related]

  • 10. [Hormonal contraception].
    Van Cauwenberge JR.
    Rev Med Liege; 1992 May 16; 47(5):221-36. PubMed ID: 1604074
    [Abstract] [Full Text] [Related]

  • 11. Bone density in women receiving depot medroxyprogesterone acetate for contraception.
    Cundy T, Evans M, Roberts H, Wattie D, Ames R, Reid IR.
    BMJ; 1991 Jul 06; 303(6793):13-6. PubMed ID: 1830502
    [Abstract] [Full Text] [Related]

  • 12. Hormonal inhibition of the endometrium for resectoscopic endometrial ablation.
    Brooks PG, Serden SP, Davos I.
    Am J Obstet Gynecol; 1991 Jun 06; 164(6 Pt 1):1601-6; discussion 1606-8. PubMed ID: 1904683
    [Abstract] [Full Text] [Related]

  • 13. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
    Handelsman DJ, Conway AJ, Howe CJ, Turner L, Mackey MA.
    J Clin Endocrinol Metab; 1996 Nov 06; 81(11):4113-21. PubMed ID: 8923869
    [Abstract] [Full Text] [Related]

  • 14. Fibrocystic breast disease: pathophysiology, pathomorphology, clinical picture, and management.
    Vorherr H.
    Am J Obstet Gynecol; 1986 Jan 06; 154(1):161-79. PubMed ID: 3511705
    [Abstract] [Full Text] [Related]

  • 15. Sustained effects on synthetic ovarian steroids of rat myometrial contractility.
    Parkington HC, Lipton A.
    J Endocrinol; 1976 Aug 06; 70(2):223-7. PubMed ID: 965882
    [Abstract] [Full Text] [Related]

  • 16. Exogenous estrogen and endometrial carcinoma: case-control and incidence study.
    McDonald TW, Annegers JF, O'Fallon WM, Dockerty MB, Malkasian GD, Kurland LT.
    Am J Obstet Gynecol; 1977 Mar 15; 127(6):572-80. PubMed ID: 190887
    [Abstract] [Full Text] [Related]

  • 17. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients.
    Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z.
    Hum Reprod; 1997 Nov 15; 12(11):2359-65. PubMed ID: 9436663
    [Abstract] [Full Text] [Related]

  • 18. A biological marker, strongly associated with early oral contraceptive use, for the selection of a high risk group for premenopausal breast cancer.
    Olsson H, Borg A, Ewers SB, Fernö M, Möller T, Ranstam J.
    Med Oncol Tumor Pharmacother; 1986 Nov 15; 3(2):77-81. PubMed ID: 3747639
    [Abstract] [Full Text] [Related]

  • 19. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis.
    Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG.
    Am J Obstet Gynecol; 1996 Aug 15; 175(2):396-401. PubMed ID: 8765259
    [Abstract] [Full Text] [Related]

  • 20. Depo Provera. Position paper on clinical use, effectiveness and side effects.
    Bigrigg A, Evans M, Gbolade B, Newton J, Pollard L, Szarewski A, Thomas C, Walling M.
    Br J Fam Plann; 1999 Jul 15; 25(2):69-76. PubMed ID: 10454658
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.